GPCR field, and serves as Deputy Director of the Australian Research Council Centre for Personalised Therapeutics Institute of Medical Research, Deputy Director of the Australian Research Council Centre for Personalised Therapeutics

GPR56 as a mechanical sensor and his sustained case for the KLF2 signaling pathway as a GPCR-linked therapeutic His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics

neuronal circuits — insights that inform next-generation functional assay development and translational therapeutic

He argues for a therapeutic strategy built around modulators that can be combined, rather than single His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics

modulate drug seeking, habit formation, and reward processing - and has been pursued as a potential therapeutic adolescent alcohol exposure disrupts mGlu2 function in the striatum in a way that might seem to close off therapeutic

mutations in the GABA-B transmembrane domain and what they suggest about precision pharmacology The therapeutic But its therapeutic window is narrow.

profiling, selectivity, and promiscuity gpcrMAX orphanMAX Chemokine obesityLITE Peptide Hormone Class B Therapeutic

By integrating advanced tools and translational biology, his work directly informs therapeutic strategies

Unconventional GPCR Ligands <p class="font_8">Watch Now</p> Terry Kenakin The New Frontier of GPCR Therapeutics

Sep 20, 2022 — First contributor article published: Therapeutic validation of an orphan G protein‐coupled

Clements' work is primarily focused on translational developments of small molecule therapeutics, and

analysis, revealed nuanced roles of RGS4, RGS9, and RGSZ — not just as modulators but as potential therapeutic

Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential signaling and drug discovery Symposium & Workshop - Brazil NEW April 1 - 3, 2025 | 2nd Peptide-Based Therapeutics Summit - USA April 2 - 3, 2025 | New therapeutic modalities: Transforming receptor pharmacology - UK Australia GPCR Jobs NEW Open Postdoctoral position - Stanford University Structural Biologist - Confo Therapeutics Pharmacologist - Schrödinger Scientist - Biology - Superluminal Medicines Scientist I Cell Biology - Tectonic Therapeutic

structural biology and drug discovery, where molecular structures inform the design and development of new therapeutics You could easily imagine separate therapeutic programs targeting those different physiological effects

Each session explores mechanistic models, translational challenges, and real-world therapeutic implications

This could accelerate discovery of therapeutic targets by combining multiplex data with focused downstream

. 🗓️ Upcoming 4-Week Course: Development of GPCR Ligands as Therapeutic Drugs starting March 20 – April biotechs public Aikium's AI-Driven mRNA Engine Looks to Address Undruggable Disordered Proteins Tectonic Therapeutic - 21, 2025 | 2nd GPCR signaling and drug discovery Symposium & Workshop NEW April 2 - 3, 2025 | New therapeutic PhD Position GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic

record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics

Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic

The canonical assumption that targeting PLC would be therapeutic has failed in the clinic, and patients

Later hepatotoxicity concerns and the success of antibody therapeutics further shifted strategy.

has reached only about 166 of them, leaving more than 250 receptors unstudied at anything close to therapeutic

to produce a distinct complex - different ligand selectivity, different signaling profile, different therapeutic

symptomatic of a deeper challenge: the field has not yet fully characterized which signaling pathways produce therapeutic

activation, and resistant to pharmacological blockade - and why those properties have shaped both the therapeutic

Whether you’re decoding signaling pathways or designing the next generation of therapeutics, Revvity

research 36:55 If not antibodies - Ball and Lin on the power of scientific communication 39:40 The GPCR therapeutic

of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics

visualization to become quantitative tools for understanding receptor activation and guiding GPCR-targeted therapeutics

. 💊 Therapeutic Potential : Understanding bias enables researchers to design drugs that target specific Kenakin challenges the traditional approach and encourages leveraging bias for better therapeutic outcomes